Literature DB >> 35880727

Sexually Dimorphic Increases in Bone Mass Following Tissue-specific Overexpression of Runx1 in Osteoclast Precursors.

Martha Elena Díaz-Hernández1,2, Christopher W Kinter1,2, Shana R Watson1,2, Giovanni Mella-Velazquez1,2, Jarred Kaiser1,2, Guanglu Liu1,2, Nazir M Khan1,2, Joseph L Roberts1,2, Joseph Lorenzo3, Hicham Drissi1,2.   

Abstract

Many metabolic bone diseases arise as a result excessive osteoclastic bone resorption, which has motivated efforts to identify new molecular targets that can inhibit the formation or activity of these bone-resorbing cells. Mounting evidence indicates that the transcription factor Runx1 acts as a transcriptional repressor of osteoclast formation. Prior studies using a conditional knockout approach suggested that Runx1 in osteoclast precursors acts as an inhibitor of osteoclastogenesis; however, the effects of upregulation of Runx1 on osteoclast formation remain unknown. In this study, we investigated the skeletal effects of conditional overexpression of Runx1 in preosteoclasts by crossing novel Runx1 gain-of-function mice (Rosa26-LSL-Runx1) with LysM-Cre transgenic mice. We observed a sex-dependent effect whereby overexpression of Runx1 in female mice increased trabecular bone microarchitectural indices and improved torsion biomechanical properties. These effects were likely mediated by delayed osteoclastogenesis and decreased bone resorption. Transcriptomics analyses during osteoclastogenesis revealed a distinct transcriptomic profile in the Runx1-overexpressing cells, with enrichment of genes related to redox signaling, apoptosis, osteoclast differentiation, and bone remodeling. These data further confirm the antiosteoclastogenic activities of Runx1 and provide new insight into the molecular targets that may mediate these effects.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  genetic mouse models; osteoclasts; redox balance; transcription factor; transcriptomics

Mesh:

Substances:

Year:  2022        PMID: 35880727      PMCID: PMC9337273          DOI: 10.1210/endocr/bqac113

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   5.051


  31 in total

1.  Deletion of Runx1 in osteoclasts impairs murine fracture healing through progressive woven bone loss and delayed cartilage remodeling.

Authors:  David N Paglia; Martha E Diaz-Hernandez; Joseph L Roberts; Judy Kalinowski; Joseph Lorenzo; Hicham Drissi
Journal:  J Orthop Res       Date:  2019-12-03       Impact factor: 3.494

2.  From brittle to ductile fracture of bone.

Authors:  Herwig Peterlik; Paul Roschger; Klaus Klaushofer; Peter Fratzl
Journal:  Nat Mater       Date:  2005-12-11       Impact factor: 43.841

Review 3.  Sites of Cre-recombinase activity in mouse lines targeting skeletal cells.

Authors:  Greig Couasnay; Maria-Bernadette Madel; Joohyun Lim; Brendan Lee; Florent Elefteriou
Journal:  J Bone Miner Res       Date:  2021-07-19       Impact factor: 6.741

4.  Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation.

Authors:  Joshua D Stender; Kyuri Kim; Tze Howe Charn; Barry Komm; Ken C N Chang; W Lee Kraus; Christopher Benner; Christopher K Glass; Benita S Katzenellenbogen
Journal:  Mol Cell Biol       Date:  2010-06-14       Impact factor: 4.272

Review 5.  Myeloperoxidase: friend and foe.

Authors:  Seymour J Klebanoff
Journal:  J Leukoc Biol       Date:  2005-02-02       Impact factor: 4.962

6.  Peroxidase enzymes inhibit osteoclast differentiation and bone resorption.

Authors:  Vasilios Panagopoulos; Vasilios Liapis; Irene Zinonos; Shelley Hay; Damien A Leach; Wendy Ingman; Mark O DeNichilo; Gerald J Atkins; David M Findlay; Andrew C W Zannettino; Andreas Evdokiou
Journal:  Mol Cell Endocrinol       Date:  2016-11-09       Impact factor: 4.102

7.  Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells.

Authors:  Xiongwei Cai; Long Gao; Li Teng; Jingping Ge; Zaw Min Oo; Ashish R Kumar; D Gary Gilliland; Philip J Mason; Kai Tan; Nancy A Speck
Journal:  Cell Stem Cell       Date:  2015-07-09       Impact factor: 24.633

8.  Runx1/AML1 hematopoietic transcription factor contributes to skeletal development in vivo.

Authors:  Jane B Lian; Eva Balint; Amjad Javed; Hicham Drissi; Regan Vitti; Edward J Quinlan; Lina Zhang; Andre J Van Wijnen; Janet L Stein; Nancy Speck; Gary S Stein
Journal:  J Cell Physiol       Date:  2003-08       Impact factor: 6.384

9.  Runx1 up-regulates chondrocyte to osteoblast lineage commitment and promotes bone formation by enhancing both chondrogenesis and osteogenesis.

Authors:  Chen-Yi Tang; Wei Chen; Yuan Luo; Jinjin Wu; Yan Zhang; Abigail McVicar; Matthew McConnell; Yuehua Liu; Hou-De Zhou; Yi-Ping Li
Journal:  Biochem J       Date:  2020-07-17       Impact factor: 3.857

Review 10.  Reactive Oxygen Species in Osteoclast Differentiation and Possible Pharmaceutical Targets of ROS-Mediated Osteoclast Diseases.

Authors:  Taiwo Samuel Agidigbi; Chaekyun Kim
Journal:  Int J Mol Sci       Date:  2019-07-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.